23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised and placebo controlled trial

Lancet

Volumn 355, Issue 9221, 2000, Pages 2106-2111

  French, N ^a,b   Nakiyingi, J ^b   Carpenter, L M ^b   Lugada, E ^b,c   Watera, C ^b   Moi, K ^b   Moore, M ^a,b   Antvelink, D ^c   Mulder, D ^b   Janoff, E N ^d   Whitworth, J ^b   Gilks, C F ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c THE AIDS SUPPORT ORGANIZATION   (Uganda)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UGANDA; VACCINATION;

EID: 0034679239     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02377-1     Document Type: Article

References (30)

1. Gilks CF, Ojoo SA, Ojoo JC, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347: 718-23.
2. Simberkoff MS, El-Sadr W, Schiffman G, Rahal-JJ. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. Am Rev Respir Dis 1984; 130: 1174-76.
3. Garcia LM, Moreno S, Rodeno P, Cercenado E, Vicente T, Bouza E. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus. Arch Intern Med 1992; 152: 1808-12.
4. Centers for Disease Control. Recommendations of the immunization practices advisory committee on pneumococcal polysaccharide vaccine. MMWR 1989; 38: 64-76.
5. Immunisation Against Infectious Diseases. London: HMSO, 1992; 167-72.
6. Janoff EN, Douglas-JM Jr, Gabriel M, et al. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J Infect Dis 1988; 158: 983-90.
7. CDC. 1999 USPHS/IDSA Guidelines for the prevention of Opportunistic Infections in Persons with Human Immunodeficiency Virus. MMWR 1999; 48: 1-59.
8. Wortley PM, Farizo KM. Adult and adolescent spectrum of HIV disease project group. Pneumococcal and influenza vaccination levels among HIV-infected adolescents and adults receiving medical care in the United States. AIDS 1994; 8: 941-44.
9. Gebo JA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 857-62.
10. Janoff EN, Fasching C, Ojoo JC, O'Brien J, Gilks CF. Responsiveness of human immunodeficiency virus type-1 infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. J Infect Dis 1997; 175: 975-78.
11. French N, Gilks CF, Mujugira A, Fasching C, O'Brien J, Janoff EN. Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures. AIDS 1998; 12: 1683-89.
12. Jones N, Huebner R, Khoosal M, Crewe-Broen H, Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12: 2177-84.
13. Gilks CF. Prophylaxis for HIV-associated infections in the developing world. J Antimicrob Chemother 1993; 31 suppl B: 119-28.
14. The WHO International Collaborating Group for the Study of the WHO Staging System. Proposed 'World Health Organization staging system for HIV infection and disease': preliminary testing by an international collaborative cross-sectional study. AIDS 1993; 7: 711-18.
15. Mulder DW, Nunn AJ, Wagner HU, Kamali A, Kengeya KJ. HIV-1 incidence and HIV-1-associated mortality in a rural Ugandan population cohort. AIDS 1994; 8: 87-92.
16. Nunn AJ, Biryahwaho B, Downing RG, van de Groen G, Ojwiya A, Mulder D. Algorithms for detecting antibodies to HIV-1: results from a rural Ugandan cohort. AIDS 1993; 7: 1057-61.
17. Carson PJ, Schut RL, Simpson ML, O'Brien J, Janoff EN. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J Infect Dis 1995; 172: 340-45.
18. Austrian R. The Quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976; 43: 699-709.
19. Caiaffa WT, Graham NMH, Vlahov D. Bacterial pnuemonia in adult populations with Human Immunodeficiency Virus (HIV) infection. Am J Epidemiol 1993; 138: 909-22.
20. Medical Research Council guidelines for good clinical practice in clinical trials. London: MRC, 1998; 1-32.
21. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-77.
22. Bruyn GA, Zegers BJ, van-Furth R. Mechanisms of host defence against infection with Streptococcus pneumoniae. Clin Infect Dis 1992; 14:251-62.
23. Brichachek B, Swindells S, Janoff EN, Pirrucello S, Stevenson M. Increased plasma Human Immunodeficiency Virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 196; 174: 1191-99.
24. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315: 1318-27.
25. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103: 281-90.
26. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351: 399-403.
27. Osterholm MT, Rambeck JH, White KE, et al, Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA 1998; 260: 1423-28.
28. Scott JAG, Hall AJ, Hannington A. Serotype distribution and prevalence of resistance to benzylpenicillin in three representative populations of Streptococcus pneumoniae isolates from the coast of Kenya. Clin Infec Dis 1998; 27: 1442-50.
29. Hibbs JR, Douglas-JM, Judson FN, McGill WL, Rietmeijer CA, Janoff EN. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteraemia at Denver General Hospital, 1984-1994. Clin Infect Dis 1997; 25: 195-99.
30. Frankel RE, Virata M, Hardalo C, Altice FL, Friedland G. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. Clin Infect Dis 1996; 23: 577-84.